Cyber reporting rules put device security on the board agenda

Tern plc

Mandatory cyber incident reporting in 2026 will make cybersecurity harder to treat as a back-office issue. Businesses will have to identify incidents faster, report them within strict deadlines and show regulators how they responded.

The rules increase compliance risk for companies that rely on connected devices, operational technology or complex digital supply chains. If a business cannot see what devices it has, how they are secured or whether they have been compromised, it may struggle to meet new reporting duties.

The pressure will be greatest where devices are widely deployed and difficult to manage manually. IoT and edge environments often involve many manufacturers, operators and service providers. That makes clear device identity, automated monitoring and reliable audit records more important.

The rules also create a stronger market backdrop for companies offering device security, Zero Trust access, credential management and lifecycle automation. Businesses will need systems that help them detect issues, prove what happened and respond within regulatory timeframes.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Device Authority strengthens position in machine identity and Zero Trust Security

Device Authority’s inclusion in two 2026 Gartner Hype Cycle reports reinforces its positioning in machine identity, IoT authentication and Zero Trust security.

Talking Medicines highlights strategic value of patient journey intelligence

Patient journey intelligence can help healthcare organisations identify care barriers and design more responsive pathways around real patient experiences.

Evidence-based care pathways support more consistent healthcare delivery

Evidence-based care pathways can improve diagnosis, treatment consistency and the integration of new therapies into routine care.

Tern increases Talking Medicines funding and raises shareholder distribution commitment

Tern has invested in additional Talking Medicines convertible loan notes and increased its minimum shareholder distribution commitment to 70% on qualifying exits.

Evidence-based care pathways create clearer routes to adoption

Evidence-based care pathways can reduce delays, improve treatment consistency and support the adoption of new therapies.

Talking Medicines highlights the data opportunity emerging around GLP-1 care

Talking Medicines examines how the expanding GLP-1 market is increasing the importance of clear distinctions between approved therapies, compounded medicines and nutritional support.

Search